Drug Trial Radar · NCT06012435
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
762
Actual
Start
Feb 21, 2024
Primary completion
May 18, 2026
Study completion May 17, 2028
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
sigvotatug vedotinDrug
Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle
docetaxelDrug
75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)Time frame: Approximately 5 years
Locations
331 sites in 25 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology, LLC
Anchorage, Alaska
Providence Medical Foundation
Fullerton, California
Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center
Fullerton, California
Providence St. Jude Medical Center
Fullerton, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Cancer Blood and Specialty Clinic
Los Alamitos, California
Regulatory Management Only: TRIO-US Central Administration
Los Angeles, California
Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharma.D.
Los Angeles, California
Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D.
Los Angeles, California
UCSF Medical Center - Mission Bay
San Francisco, California
Sansum Clinic
Santa Barbara, California
Sansum Clinic
Solvang, California
Rocky Mountain Cancer Centers LLP
Aurora, Colorado
Rocky Mountain Cancer Centers LLP
Boulder, Colorado
Rocky Mountain Cancer Centers LLP
Colorado Springs, Colorado
Rocky Mountain Cancer Centers LLP
Colorado Springs, Colorado
Rocky Mountain Cancer Centers LLP
Denver, Colorado
Rocky Mountain Cancer Centers LLP
Denver, Colorado
Rocky Mountain Cancer Centers LLP
Lakewood, Colorado
Rocky Mountain Cancer Centers LLP
Littleton, Colorado
Rocky Mountain Cancer Centers LLP
Lone Tree, Colorado
Rocky Mountain Cancer Centers LLP
Longmont, Colorado
Rocky Mountain Cancer Centers LLP
Pueblo, Colorado
Rocky Mountain Cancer Centers LLP
Thornton, Colorado
Cancer Specialists of North Florida
Fleming Island, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Cancer Care Centers of Brevard, Inc.
Melbourne, Florida
Baptist Hospital of Miami
Miami, Florida
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida
Cancer Specialists of North Florida
Neptune Beach, Florida
Cancer Care Centers of Brevard, Inc.
Palm Bay, Florida
Cancer Care Centers of Brevard, Inc.
Rockledge, Florida
Cancer Specialists of North Florida
Saint Augustine, Florida
Illinois Cancer Specialists
Arlington Heights, Illinois
Illinois Cancer Specialists
Niles, Illinois
Maryland Oncology Hematology P.A.
Annapolis, Maryland
Maryland Oncology Hematology P.A.
Bethesda, Maryland
Showing 40 of 331 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.